Want to see AKTX full AI Analyst Report?
Akari Therapeutics (AKTX) Income Statement
Akari Therapeutics Income Statement
Last quarter (Q2 2026), Akari Therapeutics's total revenue was $0.00. In Q2, Akari Therapeutics's net income was $-4.81M. See Akari Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 17.27M | $ 21.64M | $ 16.81M | $ 23.09M | $ 17.21M | |
| Depreciation and Amortization | $ 0.00 | $ 14.00K | $ 4.00K | $ 4.00K | $ 4.13K |
| $ -17.35M | $ -19.53M | $ -10.00M | $ -17.74M | $ -17.42M | |
| $ -17.27M | $ -21.64M | $ -16.81M | $ -23.09M | $ -17.21M | |
| $ -1.03M | $ 1.85M | $ 6.80M | $ 5.34M | $ -210.10K | |
| $ -18.30M | $ -19.79M | $ -10.01M | $ -17.75M | $ -17.42M | |
| $ -17.30M | $ -19.79M | $ -10.01M | $ -17.75M | $ -17.42M | |
| Per Share Metrics | |||||
| Basic EPS | $ -20800.00 | $ -132800.00 | $ -163200.00 | $ -455200.00 | $ -649600.00 |
| Diluted EPS | $ -20800.00 | $ -132800.00 | $ -163200.00 | $ -455200.00 | $ -649600.00 |
| Weighted Average Shares Outstanding | 21.04K | 5.97K | 2.45K | 1.56K | 1.07K |
| Weighted Average Shares Outstanding (Diluted) | 21.04K | 5.97K | 2.45K | 1.56K | 1.07K |
Currency in USD
